You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥(06996.HK)急漲16%重越上市價 成交倍增
阿思達克 06-23 13:27
德琪醫藥-B(06996.HK)扭兩連跌,股價兩個月來首次重越上市價18.08元,最高見19.2元,現造18.7元,急漲16%,成交倍增至699萬股,涉資1.26億元。

德琪上月下旬宣佈,於中國完成Eltanexor(ATG-016)第一/二期臨牀試驗首例患者給藥,用於治療去甲基化藥物治療失敗的IPSS-R(國際預後積分系統修訂版)中危及以上的骨髓增生異常綜合症患者。

德琪是一家專注於創新抗腫瘤藥物亞太地區臨牀階段生物製藥公司。股份去年11月中旬以每18.08元在港上市,淨籌約26.36億元,主要用作分配予集團核心產品、爲集團其他四個臨牀階段候選藥物提供資金、用於管線中其他臨牀前候選藥物正在進行臨牀前研究及計劃進行臨牀試驗,以及擴大其研發管線等。股份掛牌後高低位分別於今年1月及3月所造22.5元及14.48元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account